GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (FRA:I4AA) » Definitions » Cyclically Adjusted Book per Share

IntelliPharmaCeutics International (FRA:I4AA) Cyclically Adjusted Book per Share : €0.14 (As of Aug. 2023)


View and export this data going back to 2013. Start your Free Trial

What is IntelliPharmaCeutics International Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

IntelliPharmaCeutics International's adjusted book value per share for the three months ended in Aug. 2023 was €-0.357. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.14 for the trailing ten years ended in Aug. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-09-21), IntelliPharmaCeutics International's current stock price is €0.0445. IntelliPharmaCeutics International's Cyclically Adjusted Book per Share for the quarter that ended in Aug. 2023 was €0.14. IntelliPharmaCeutics International's Cyclically Adjusted PB Ratio of today is 0.32.


IntelliPharmaCeutics International Cyclically Adjusted Book per Share Historical Data

The historical data trend for IntelliPharmaCeutics International's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Cyclically Adjusted Book per Share Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.06 -0.06 0.02 -

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.12 0.14 0.14

Competitive Comparison of IntelliPharmaCeutics International's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, IntelliPharmaCeutics International's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Cyclically Adjusted PB Ratio falls into.



IntelliPharmaCeutics International Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, IntelliPharmaCeutics International's adjusted Book Value per Share data for the three months ended in Aug. 2023 was:

Adj_Book= Book Value per Share /CPI of Aug. 2023 (Change)*Current CPI (Aug. 2023)
=-0.357/125.3885*125.3885
=-0.357

Current CPI (Aug. 2023) = 125.3885.

IntelliPharmaCeutics International Quarterly Data

Book Value per Share CPI Adj_Book
201311 -2.059 97.182 -2.657
201402 2.212 98.051 2.829
201405 2.239 99.394 2.825
201408 1.798 99.315 2.270
201411 1.678 99.078 2.124
201502 1.568 99.078 1.984
201505 1.116 100.263 1.396
201508 0.874 100.579 1.090
201511 -0.053 100.421 -0.066
201602 -0.388 100.421 -0.484
201605 -0.695 101.765 -0.856
201608 0.540 101.686 0.666
201611 0.347 101.607 0.428
201702 0.271 102.476 0.332
201705 0.239 103.108 0.291
201708 -0.217 103.108 -0.264
201711 0.095 103.740 0.115
201802 -0.636 104.688 -0.762
201805 -0.200 105.399 -0.238
201808 -0.986 106.031 -1.166
201811 0.198 105.478 0.235
201902 0.036 106.268 0.042
201905 -0.041 107.927 -0.048
201908 -0.098 108.085 -0.114
201911 -0.151 107.769 -0.176
202002 -0.187 108.559 -0.216
202005 -0.225 107.532 -0.262
202008 -0.167 108.243 -0.193
202011 -0.226 108.796 -0.260
202102 -0.251 109.745 -0.287
202105 -0.125 111.404 -0.141
202108 -0.158 112.668 -0.176
202111 -0.216 113.932 -0.238
202202 -0.240 115.986 -0.259
202205 -0.282 120.016 -0.295
202208 -0.303 120.569 -0.315
202211 -0.314 121.675 -0.324
202302 -0.309 122.070 -0.317
202305 -0.305 124.045 -0.308
202308 -0.357 125.389 -0.357

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


IntelliPharmaCeutics International  (FRA:I4AA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

IntelliPharmaCeutics International's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.0445/0.14
=0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


IntelliPharmaCeutics International Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International Headlines

No Headlines